RxDoctor Payments Data

Alexey Levashkevich, MD

Obstetrics · Flint, MINPI 1124140405

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,790 of the $22,660 with a category attached, or 69.7%. Coloplast accounts for 86.6% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $13,694, more than ten times the $1,303 reported in 2019. Among obstetrics clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,660in general payments, 2019–2025

Across 194 payments — averaging $116.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$20K
  • Intuitive Surgical$830
  • Medtronic$574
  • AbbVie$384
  • Coopersurgical, Inc.$131
  • Ascend Therapeutics US, LLC$127
  • plus $982 from 17 others

What the payments were for

  • Consulting fees$15,79070%
  • Travel & lodging$3,19614%
  • Food & beverage$3,42415%
  • Education$310%
  • Gifts$2191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,660 in reported general payments places this provider in the 95th percentile of 48 obstetrics providers in Michigan.

See all obstetrics providers in Michigan

Medicare billing

Part B allowed, 2024
$53,004
Medicare patients
66
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron50$30,060
Mirabegron ErMirabegron39$18,232
Estradiol47$3,163
Oxybutynin Chloride62$494
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$297
Oxybutynin Chloride ErOxybutynin Chloride11$242
Ciprofloxacin Hcl50$124
Cyclobenzaprine Hcl11$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$91$30,06050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 obstetrics providers in Michigan.

Other obstetrics in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →